Management of high-risk populations with locally advanced prostate cancer

被引:28
|
作者
Khan, MA [1 ]
Partin, AW [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
来源
ONCOLOGIST | 2003年 / 8卷 / 03期
关键词
locally advanced prostate cancer; risk factors; management;
D O I
10.1634/theoncologist.8-3-259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer that extends beyond the confines of the prostatic gland on clinical and/or radiographic assessment, without evidence of lymph node or distant metastases, is regarded as locally advanced. The locally advanced prostate cancer patient population consists of a heterogeneous group of men, some of whom have tumors that may be amenable to primary curative intent with local definitive therapy associated with acceptable long-term cancer control rates. In order to optimally manage this group of patients, it is important to be able to recognize who is at a high risk of tumor recurrence after primary local therapy. In this brief review, we discuss the factors that contribute to the prediction of high risk in populations with locally advanced disease and the treatment options available.
引用
收藏
页码:259 / 269
页数:11
相关论文
共 50 条
  • [1] The management of high-risk, locally advanced, prostate cancer radiation therapy
    Sridharan, Swetha
    Warde, Padraig
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2012, 6 (05): : 393 - 395
  • [2] Treatment strategies for high-risk locally advanced prostate cancer
    Seth A. Rosenthal
    Howard M. Sandler
    [J]. Nature Reviews Urology, 2010, 7 : 31 - 38
  • [3] Treatment strategies for high-risk locally advanced prostate cancer
    Rosenthal, Seth A.
    Sandler, Howard M.
    [J]. NATURE REVIEWS UROLOGY, 2010, 7 (01) : 31 - 38
  • [4] Multimodal treatment of high-risk and locally advanced prostate cancer
    Preisser, Felix
    Tilki, Derya
    [J]. UROLOGIE, 2022, 61 (12): : 1341 - 1344
  • [5] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    John Thoms
    Jayant S. Goda
    Alexender R. Zlotta
    Neil E. Fleshner
    Theodorus H. van der Kwast
    Stéphane Supiot
    Padraig Warde
    Robert G. Bristow
    [J]. Nature Reviews Clinical Oncology, 2011, 8 : 107 - 113
  • [6] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    Thoms, John
    Goda, Jayant S.
    Zlotta, Alexendre R.
    Fleshner, Neil E.
    van der Kwast, Theodorus H.
    Supiot, St Phane
    Warde, Padraig
    Bristow, Robert G.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (02) : 107 - 113
  • [7] The importance of local control in high-risk locally advanced prostate cancer
    Sridharan, S.
    Warde, P.
    [J]. CURRENT ONCOLOGY, 2012, 19 : S6 - S12
  • [8] High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key
    Terlizzi, Mario
    Bossi, Alberto
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2022, 38 : 14 - 16
  • [9] ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
    McLaughlin, Patrick W.
    Liss, Adam L.
    Nguyen, Paul L.
    Assimas, Dean G.
    D'Amico, Anthony V.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    Keol, Sameer R.
    Liauw, Stanley L.
    Lloyd, Shane
    Movsas, Benjamin
    Prestidg, Bradley R.
    Showalter, Timothy N.
    Taira, Al V.
    Vapiwal, Neha
    Davi, Brian J.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 1 - 10
  • [10] Improving the diagnosis and treatment of high-risk localised or locally advanced prostate cancer
    Payne, Heather
    Khoo, Vincent
    Clarke, Noel
    Beresford, Mark
    Moore, Caroline
    Aslett, Philippa
    Bahl, Amit
    Bhatt, Rupesh
    Boustead, Greg
    Brewster, Simon
    Kirby, Roger
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2015, 6 (01) : 26 - 30